Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Primrose Bio raises new capital led by Signet Healthcare Partners and adds James Gale to its board to support platform expansion.

Rhea-AI Summary

Primrose Bio closed a new financing round led by healthcare-focused investor Signet Healthcare Partners, with significant participation from existing backers 1315 Capital, Ligand Pharmaceuticals (LGND), LDV Partners and Agent Capital. James Gale, Founding Partner and Managing Director of Signet, joined Primrose Bio’s board of directors in connection with the investment.

The company plans to use the proceeds to expand the reach and capabilities of its technology portfolio, including Pfenex Expression Technology for high-yield protein production used in six approved biologics, Prima RNApols RNA polymerases for scalable mRNA manufacturing, and PeliCRM197, a validated carrier protein used in multiple approved vaccines. Primrose’s leadership stated that the capital will support broader adoption of these platforms and help customers advance therapeutic and vaccine programs toward clinical trials.

Market Context

Before publication, LGND's prior daily close had risen 2.32%; the article identified Ligand as an ex...

Analysis

Before publication, LGND's prior daily close had risen 2.32%; the article identified Ligand as an existing participant in Primrose's financing, while no post-publication price reaction was supplied.

Key Figures

Approved biologics: 6 approved biologics

Approved biologics

6 approved biologics

Products using Pfenex Expression Technology

Key Terms

microbial expression platform, rna polymerases, ruo, gmp-grade

4 terms

microbial expression platform technical

"a scalable microbial expression platform for efficient, high-yield production"

A microbial expression platform is a laboratory and manufacturing system that uses engineered microbes—such as bacteria, yeast, or other single‑celled organisms—to produce a target biological product like a protein, enzyme, vaccine component, or small molecule. Think of it as a factory where living cells are programmed to make a desired product; it matters to investors because the choice of microorganism, the platform’s yield, scalability, regulatory track record, and intellectual property affect manufacturing cost, speed to market, and commercial viability.

rna polymerases technical

"proprietary RNA polymerases for consistent, scalable, high-quality mRNA manufacturing"

Enzymes that read DNA and build matching RNA copies, like factory machines that transcribe written blueprints into working instructions cells use to make proteins. Different types of RNA polymerases make different kinds of RNA (messenger RNA, ribosomal RNA, etc.), so they are central to how genes are expressed. Investors encounter the term in biotechnology and drug-development contexts because many therapies and diagnostics target, use, or depend on RNA polymerase activity.

ruo regulatory

"available in RUO- and GMP-grade"

RUO (Research Use Only) is a label for laboratory tests, instruments, or reagents that are intended solely for scientific research and not for diagnosing or treating patients. For investors, RUO status matters because it limits where and how a product can be sold—think of it like a prototype car that can be driven on a test track but not licensed for public roads, which narrows revenue opportunities and avoids certain regulatory approvals.

gmp-grade regulatory

"available in RUO- and GMP-grade"

GMP-grade means a drug substance, ingredient or product was manufactured under Good Manufacturing Practice standards — a set of rules and documented controls that ensure consistent cleanliness, quality and traceability. For investors, GMP-grade items matter because they lower regulatory and safety risk, make products eligible for approval and sale in regulated markets, and reduce the chance of costly recalls or supply disruptions; think of it like food prepared in a certified commercial kitchen rather than a home stove.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors.

The proceeds will help Primrose continue to expand the reach and capabilities of its differentiated technology portfolio:

• Pfenex Expression Technology^® ("Pfenex"), a scalable microbial expression platform for efficient, high-yield production of complex, engineered proteins used in six approved biologics
• Prima RNApols^®, proprietary RNA polymerases for consistent, scalable, high-quality mRNA manufacturing (available in RUO- and GMP-grade)
• PeliCRM197^®, a validated carrier protein used in multiple approved vaccines (RUO and GMP) 

"This financing marks an important next step for Primrose and reflects confidence in our technologies, team and commercial opportunity," said Andrew Burch, Chief Executive Officer of Primrose Bio. "As the engineering of biologic and nucleic acid medicines advances, developers need more robust production systems that also improve quality, yield, speed, scalability and cost. This capital will help us broaden adoption, enhance capabilities and accelerate customers moving therapeutic and vaccine programs forward toward clinical trials." 

"Signet sees a compelling opportunity across Primrose's portfolio," said James Gale. "Having partnered with The Dow Chemical Company to establish Pfenex Inc. in 2009, we have seen the platform's commercial value firsthand. Primrose is building on that foundation with further advances in Pfenex technology as well as Prima RNApols and PeliCRM197. We are pleased to invest in this next phase of growth and support the team as they scale the business and help more customers improve manufacturing performance across multiple therapeutic modalities."

About Primrose Bio, Inc.

Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production. Primrose's major offerings include Pfenex Expression Technology^®: a proprietary microbial production system used in six approved products with up to 20x higher yields and a strong record across diverse protein modalities; Prima RNApols^®: improved enzymes for mRNA manufacturing; and PeliCRM197^®: a commercially validated CRM197 carrier protein used for conjugate vaccines.  Several of the world's leading pharmaceutical companies use Primrose's technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen, and Serum Institute of India. For more information, please visit: www.primrosebio.com.

About Signet Healthcare Partners

Signet Healthcare Partners is a healthcare growth equity firm that invests in commercial-stage pharmaceutical (pharma services and therapeutics) and medical technology companies. Founded in 1998 and based in New York, Signet has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks. For more information, please visit: www.signethealthcarepartners.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/primrose-bio-raises-significant-growth-capital-investment-led-by-signet-healthcare-partners-302886141.html

SOURCE Primrose Bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How does Primrose Bio intend to use the new financing proceeds?

Primrose Bio plans to use the capital to expand the reach and capabilities of its technology portfolio. The company said this includes further developing and scaling its Pfenex Expression Technology platform for complex protein production, Prima RNApols RNA polymerases for consistent mRNA manufacturing, and PeliCRM197 carrier protein used in approved vaccines. The funding is also intended to help broaden adoption of these technologies and accelerate customers’ therapeutic and vaccine programs toward clinical trials.

What products are included in Primrose Bio’s technology portfolio mentioned in the financing announcement?

The portfolio highlighted in the announcement includes:

• Pfenex Expression Technology, a scalable microbial expression platform used for efficient, high-yield production of complex, engineered proteins used in six approved biologics.
• Prima RNApols, proprietary RNA polymerases for consistent, scalable, high-quality mRNA manufacturing, available in both RUO and GMP grades.
• PeliCRM197, a validated carrier protein used in multiple approved vaccines, also offered in RUO and GMP forms.

What governance change accompanied the Primrose Bio financing round?

In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet Healthcare Partners, joined Primrose Bio’s Board of Directors.